MedTrace Logo

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome

NCT01501461 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2018-04-19

No results posted yet for this study

Summary

The intent of this clinical study is to answer the questions:

1. Is the proposed treatment safe
2. Is treatment effective in improving the health of patients with human frailty syndrome.

Conditions

  • Frailty Syndrome

Interventions

PROCEDURE

Harvesting and implantation of stem cells

The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.

Sponsors & Collaborators

  • Instituto de Medicina Regenerativa

    collaborator INDUSTRY

  • Ageless Regenerative Institute

    lead INDUSTRY

Principal Investigators

  • Clemente Zuniga, MD · Instituto de Medicina Regenerativa

  • Jesus A Perez, MD · Instituto de Medicina Regenerativa

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-01
Primary Completion
2017-05-30
Completion
2017-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01501461 on ClinicalTrials.gov